前收市價 | 20.56 |
開市 | 20.26 |
買盤 | 19.73 x 100 |
賣出價 | 19.93 x 100 |
今日波幅 | 19.69 - 20.26 |
52 週波幅 | 19.69 - 79.65 |
成交量 | |
平均成交量 | 657,135 |
市值 | 1.062B |
Beta 值 (5 年,每月) | 0.24 |
市盈率 (最近 12 個月) | 無 |
每股盈利 (最近 12 個月) | -2.76 |
業績公佈日 | 2024年4月29日 - 2024年5月03日 |
遠期股息及收益率 | 無 (無) |
除息日 | 無 |
1 年預測目標價 | 66.77 |
The Alzheimer's treatment space is heating up — and could soon leave Eli Lilly's embattled drug, donanemab, in the dust, experts say.
Per Biogen (BIIB)/Eisai, the delay in CHMP recommendation for lecanemab is entirely related to procedural reasons at the EMA and is not related to the companies' regulatory filing.
Prothena (PRTA) posts a wider-than-expected loss in the fourth quarter on lower revenues and higher costs.